undamentalytics Newsletter

Atricure, Inc. key statistics and ratios

In fiscal 2025, Atricure, Inc. had return on equity of -2.4% and a net margin of -2.1%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Atricure, Inc.: financial ratios, annual
Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Net margin−30.2%−6.4%−8.5%−10.7%−14.0%−15.1%−21.0%−21.5%−15.4%−10.5%−15.2%−23.3%18.3%−14.1%−7.6%−9.6%−2.1%1.9%
Return on equity−96.5%−22.4%−33.7%−53.6%−26.9%−15.8%−17.0%−18.8%−16.3%−10.3%−14.2%−14.6%11.2%−9.9%−6.6%−9.6%−2.4%2.1%
Return on assets—−11.2%−16.1%−22.7%−15.9%−12.0%−12.6%−12.1%−9.9%−6.8%−7.7%−7.6%7.5%−7.7%−5.1%−7.3%−1.8%1.6%
Effective tax rate————————————0.4%————12.8%
R&D as % of revenue20.9%19.5%18.4%17.3%16.4%17.3%19.8%23.1%19.5%17.2%17.9%20.9%17.7%17.4%18.5%20.7%18.6%17.2%
SG&A as % of revenue64.4%62.8%61.9%64.2%69.6%68.4%72.3%68.6%67.0%64.2%72.4%73.0%74.6%70.0%63.4%62.6%58.2%56.8%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

6 of 7 checks passed · June 30, 2026
What it owns · $677m
Short-term assets $346mLonger-term assets $331m
What it owes, and who funded it · $677m
Short-term liabilities $82mLonger-term liabilities $78mShareholders' equity $516m
  • Short-term assets cover short-term liabilities $346m of assets due within a year against $82m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $346m short-term assets against $78m of longer-dated liabilities.
  • More cash than debt $168m of cash against $61m of debt.
  • Debt below 40% of shareholders' equity Debt is 12% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 12% to 12% over five years.
  • A year's operating cash flow covers at least 20% of debt $65m of operating cash flow against $61m of debt.
  • Operating profit covers interest at least five times over Operating income of $13m against $6m of interest.

From Atricure, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

39 /100

Weak moat

How hard Atricure's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 2 / 20

    Cash operating profit has been a median 3.1% of total assets over 10 years.

  • Pricing power 20 / 20

    Gross margin has been a median 74.7%, moving by 1.4 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -8.2%; its worst year was -22.0%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 2 of 10 years, at a median -5.3% of revenue.

  • Discipline 6 / 20

    The diluted share count rose 9.0% over five years; stock-based pay has been a median 8.5% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ATRC vs BVSATRC vs TMDXAORT vs ATRC

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Atricure, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Atricure, Inc.